Journal article

Effects of simvastatin, rosuvastatin and pravastatin on soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG) secretion from human umbilical vein endothelial cells, primary trophoblast cells and placenta

Fiona C Brownfoot, Stephen Tong, Natalie J Hannan, Roxanne Hastie, Ping Cannon, Tu'uhevaha J Kaitu'u-Lino

BMC PREGNANCY AND CHILDBIRTH | BMC | Published : 2016

Abstract

BACKGROUND: Preeclampsia is associated with the placental release of soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin (sENG). These anti-angiogenic factors cause hypertension and multi-organ injury. Pravastatin decreases placental secretion of sFlt-1 in vitro and is currently being examined in clinical trials as a potential treatment for preeclampsia. However, it is possible that different classes of statins may be more potent at decreasing sFlt-1 secretion. We compared the relative potency of three different generations of statins on sFlt-1 and sENG secretion from human endothelial cells, trophoblast cells, and placenta explants. METHODS: We performed functional experiments ..

View full abstract

Grants

Awarded by National Health and Medical Research Council of Australia (NHMRC)


Awarded by NHMRC


Funding Acknowledgements

This work was funded by The National Health and Medical Research Council of Australia (NHMRC; #1048707, #1046484) and an Arthur Wilson RANZCOG scholarship. FB was supported by an Australian Postgraduate Award and an AVANT scholarship. The NHMRC provided salary support (#1050765 to ST #1062418 to TKL). The University of Melbourne provided salary support to NJH (CR Roper Fellowship). The funders had no role in study design, data collection, analysis, decision to publish or preparation of the manuscript.